Home・Lista de Ações・MannKind Corp

MannKind Corp

Fechado

SetorSaúde

3.84

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.83

Máximo

3.91

Indicadores-chave
By Trading Economics
Rendimento	-2.4M -19M
Vendas	19M 109M
P/E Médio do Setor	140.5 57.002
EPS	-0.06
Margem de lucro	-17.401
Funcionários	591
EBITDA	10M 13M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+115.89% upside

Dividendos
By Acuity
Próximos Ganhos	4 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	90M 1.3B
Abertura anterior	3.84
Fecho anterior	3.84

Sentimento de Notícias

By Acuity

50%

135 / 340 Ranking em Healthcare

MannKind Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de ago. de 2026, 23:46 UTC

MannKind shares are higher in after-market trading, reflecting a slight recovery amid a cautious market ahead of the upcoming consumer price index report.

10 de ago. de 2026, 22:56 UTC

MannKind Corp shares are higher in after-market hours following Monday's close, though no specific news was identified to explain the price movement.

7 de ago. de 2026, 23:01 UTC

MannKind Corp shares declined in after-market trading, reflecting notable weakness despite remaining above the 20-day moving average. No specific news was identified.

6 de ago. de 2026, 22:01 UTC

MannKind Corp shares are lower in after-market trading, reflecting broader market weakness and trading below their 20-day moving average. No specific news was identified.

5 de ago. de 2026, 23:02 UTC

News

MannKind Corp shares declined after-hours following a second-quarter earnings miss, despite reporting revenues of $109.4 million and FDA approvals for new products.

4 de ago. de 2026, 23:26 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified to explain the price movement. Trading has remained within a narrow range.

3 de ago. de 2026, 22:51 UTC

MannKind Corp shares are higher in after-market trading, reflecting momentum since Monday's close amid falling Brent crude oil prices and positive market sentiment.

31 de jul. de 2026, 23:56 UTC

MannKind Corp shares traded lower in after-market hours, retreating from earlier gains. The stock remains near the lower end of its one-month range.

30 de jul. de 2026, 18:41 UTC

Event

News

Wells Fargo raised MannKind's price target to $14.00, contributing to positive momentum. The company also reported favorable Phase 1b study results today.

29 de jul. de 2026, 19:47 UTC

News

Event

MannKind Corp reported positive results from its Phase 1b INFLO-1 study, but shares are trading lower amid broader market uncertainty ahead of the Fed's decision.

28 de jul. de 2026, 21:01 UTC

News

MannKind Corp will report its second quarter 2026 financial results on August 5, 2026. Shares are trading higher in after-market hours.

27 de jul. de 2026, 22:06 UTC

MannKind Corp shares are higher in after-market trading, despite earlier declines. No specific news was identified to explain the price movement.

24 de jul. de 2026, 21:01 UTC

Event

MannKind Corp shares are rising in after-market trading following FDA approval of Furoscix ReadyFlow™ for treating edema in heart failure and chronic kidney disease.

23 de jul. de 2026, 10:36 UTC

MannKind Corp shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite declines in the broader tech sector.

22 de jul. de 2026, 21:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting a gain since Wednesday's close, despite remaining below the 20-day moving average.

21 de jul. de 2026, 22:11 UTC

MannKind Corp shares rose in after-market trading, reflecting a broader rebound in technology stocks and strong interest in semiconductor and AI investments.

Comparação entre Pares

Variação de preço

MannKind Corp Previsão

Preço-alvo

By TipRanks

115.89% parte superior

Previsão para 12 meses

Média 8.29 USD 115.89%

Máximo 13 USD

Mínimo 4.75 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para MannKind Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

Comprar

Manter

Vender

Com base em 6 analistas que deram avaliações de ações para MannKind Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

135 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.